Rankings
▼
Calendar
SLNO Q2 2024 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
SLNO
Soleno Therapeutics, Inc.
$2B
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$494,000
Operating Income
-$23M
Net Income
-$22M
EPS (Diluted)
$-0.57
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$18M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$304M
Total Liabilities
$23M
Stockholders' Equity
$281M
Cash & Equivalents
$57M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$494,000
$0
—
Operating Income
-$23M
-$9M
-169.4%
Net Income
-$22M
-$8M
-157.9%
← FY 2024
All Quarters
Q3 2024 →